AMRN Amarin Corporation plc

3.18
+0  (0%)
Previous Close 3.17
Open 3.20
Price To book 0.00
Market Cap 865.15M
Shares 272,061,000
Volume 578,785
Short Ratio 3.25
Av. Daily Volume 1,451,780

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Interim analysis announced September 12, 2016 - trial to proceed.Second interim analysis due late 3Q 2017. Final data due 2018.
Vascepa REDUCE-IT outcomes trial
High Triglycerides With Mixed Dyslipidemia

Latest News

  1. Overseas Earnings Estimated to Outdo US: Top 5 Gainers
  2. ETFs with exposure to Amarin Corp. Plc : April 7, 2017
  3. 3 Stocks the Smartest Investors Are Buying Right Now
  4. 3 Stocks That Could Make You Rich
  5. 4 Biotech Stocks With Jaw-Dropping Growth Potential
  6. Amarin Corporation CEO, John Thero, to Chair the American Heart Association’s Heart & Stroke Ball in New York City
  7. Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study
  8. Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology
  9. Amarin Corp. Plc :AMRN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  10. Here's What Pushed Amarin Corporation plc 15% Higher in February
  11. Amarin reports 4Q loss
  12. Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations
  13. Amarin to Report Fourth Quarter and Full Year 2016 Results and Host Conference Call on February 28th, 2017
  14. Amarin to Participate in the Leerink Partners 6th Annual Global Healthcare Conference
  15. FDA issues draft guidance to better medical product labeling
  16. More Innovation, Less Regulation: 2 Biotech Stocks That Could Soar in 2017
  17. 1 Reason Amarin's Stock Skyrocketed in 2016